In the trastuzumab-treated group though, there was a significant association between CD32B + B-CLS and shorter time to metastatic disease compared to patients with no CD32B + B-CLS in patients with BMI ≥ 25 kg/m2 (p = 0.003) (Fig. 5e). The gene discussed is FCGR2B; the disease is metastatic neoplasm.